Expression Profiling of Palmitate- and Oleate-Regulated Genes Provides Novel Insights Into the Effects of Chronic Lipid Exposure on Pancreatic β-Cell Function
- 1Garvan Institute of Medical Research, St. Vincent’s Hospital, Sydney, Australia
- 2Department of Biochemistry, University of Sydney, Sydney, Australia
Abstract
Chronic lipid exposure is implicated in β-cell dysfunction in type 2 diabetes. We therefore used oligonucleotide arrays to define global alterations in gene expression in MIN6 cells after 48-h pretreatment with oleate or palmitate. Altogether, 126 genes were altered ≥1.9-fold by palmitate, 62 by oleate, and 46 by both lipids. Importantly, nine of the palmitate-regulated genes are known to be correspondingly changed in models of type 2 diabetes. A tendency toward β-cell de-differentiation was also apparent with palmitate: pyruvate carboxylase and mitochondrial glycerol 3-phosphate dehydrogenase were downregulated, whereas lactate dehydrogenase and fructose 1,6-bisphosphatases were induced. Increases in the latter (also seen with oleate), along with glucosamine-phosphate n-acetyl transferase, imply upregulation of the hexosamine biosynthesis pathway in palmitate-treated cells. However, palmitate also increased expression of calcyclin and 25-kDa synaptosomal-associated protein (SNAP25), which control distal secretory processes. Consistent with these findings, secretory responses to noncarbohydrate stimuli, especially palmitate itself, were upregulated in palmitate-treated cells (much less so with oleate). Indeed, glucose-stimulated secretion was slightly sensitized by chronic palmitate exposure but inhibited by oleate treatment, whereas both lipids enhanced basal secretion. Oleate and palmitate also induced expression of chemokines (MCP-1 and GRO1 oncogene) and genes of the acute phase response (serum amyloid A3). Increases in transcriptional modulators such as ATF3, CCAAT/enhancer binding protein-β (C/EBPβ), C/EBPδ, and c-fos were also seen. The results highlight links between regulated gene expression and phenotypic alterations in palmitate versus oleate-pretreated β-cells.
Footnotes
-
Address correspondence and reprint requests to Dr. Trevor Biden, Cell Signalling Group, Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, Sydney 2010, Australia. Email: t.biden{at}garvan.org.au.
Received for publication 21 September 2001 and accepted in revised form 8 January 2002.
C/EBP, CCAAT/enhancer binding protein; DMEM, Dulbecco’s modified Eagle’s medium; FA, fatty acid; FBPase, fructose 1,6-bisphosphatase; GPAT, glucosamine-phosphate n-acetyl transferase; HBP, hexosamine biosynthesis pathway; ICER, inducible cAMP early repressor; KRB, Krebs-Ringer bicarbonate; LDH, lactate dehydrogenase; mGPDH, mitochondrial glycerol 3-phosphate dehydrogenase; PAP2, phosphatidic acid phosphohydrolase 2; PC, pyruvate carboxylase; PDX-1, pancreatic duodenal homeobox-1; PKC, protein kinase C; PLD, phospholipase D; SNAP25, 25-kDa synaptosomal-associated protein; TPA, 12-O-tetradecanoylphorbol-13-acetate.
- DIABETES











